Trial · NCT05414292
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
NCT05414292, Not applicable, Recruiting, University of Nottingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune). Trials, record NCT05414292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05414292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
- NCT number
- NCT05414292
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 16 participants, estimated
- Lead sponsor
- University of Nottingham
- Conditions
- Muscle Atrophy, Age-Related Sarcopenia
- Interventions
- Rapamune (sirolimus) 1Mg Tablet, Unilateral resistance exercise training
- First posted
- 2022-06-10
- Last updated
- 2025-04-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in muscle mass from baseline | 0 and 16 weeks | To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles. |
| Primary | Change in muscle mass from baseline | 0 and 8 weeks | To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles. |
| Primary | Change in muscle mass from baseline | 0 and 5 weeks | To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles. |
| Secondary | Change in muscle strength | 0, 5, 8 and 16 weeks | To determine the impacts of rapamycin on muscle function through muscle strength measures of 1 Repetition Maximum |
| Secondary | Change in muscle power | 0, 5, 8 and 16 weeks | To determine the impacts of rapamycin on muscle function through muscle power measured from countermovement jump analysis. |
| Secondary | Change in muscle function | 0, 5, 8 and 16 weeks | To determine the impacts of rapamycin on muscle function through muscle performance measures included in the short performance physical battery test (SPPBT). |
| Secondary | Change in neuromuscular function | 0, 5, 8 and 16 weeks | • To determine the impacts of rapamycin on muscle function through muscle-nerve electrical signals studied with electromyography (EMG). |
| Secondary | Change in Muscle Protein Synthesis | 2, 5, and 8 weeks | To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein synthesis (via D2O tracer) from muscle biopsies. |
| Secondary | Change in Muscle Protein Breakdown | 2 and 16 weeks | To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein breakdown (via 3-MH tracer) obtained from muscle biopsies. |
| Secondary | Immune function | 0, 2, 5, 8 and 16 weeks | Collection of peripheral blood mononuclear cells to study the immune cytokine profile using an Isoplexis system |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05414292
GET https://conductscience.org/api/trials/v1/NCT05414292/registered